Telaprevir
- Generic Name
- Telaprevir
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C36H53N7O6
- CAS Number
- 402957-28-2
- Unique Ingredient Identifier
- 655M5O3W0U
- Background
Telaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of...
- Indication
Telaprevir, when used in combination with Ribavirin, Peginterferon alfa-2a, and Peginterferon alfa-2b is indicated for use in the treatment of chronic HCV genotype 1 infection in adults .
- Associated Conditions
- Chronic Hepatitis C Genotype 1
- Associated Therapies
- -
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
- Conditions
- Interventions
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 540
- Registration Number
- NCT00758043
A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
- Conditions
- Interventions
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Tibotec BVBA
- Target Recruit Count
- 663
- Registration Number
- NCT00703118
A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)
- Conditions
- Interventions
- First Posted Date
- 2008-03-04
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 1095
- Registration Number
- NCT00627926
An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2007-12-27
- Last Posted Date
- 2013-09-09
- Lead Sponsor
- Tibotec BVBA
- Target Recruit Count
- 24
- Registration Number
- NCT00580801
A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection
- Conditions
- Interventions
- First Posted Date
- 2007-11-20
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Tibotec BVBA
- Target Recruit Count
- 52
- Registration Number
- NCT00561015
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy
- Conditions
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 117
- Registration Number
- NCT00535847
- Locations
- 🇺🇸
Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸South Denver Gastroenterology, Englewood, Colorado, United States
🇺🇸University of Florida, Gainesville, Florida, United States
An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants
- Conditions
- Interventions
- First Posted Date
- 2007-09-12
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Tibotec BVBA
- Target Recruit Count
- 166
- Registration Number
- NCT00528528
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
- Conditions
- Interventions
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 465
- Registration Number
- NCT00420784
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇳🇱Academic Medical Center, Amsterdam, Netherlands
🇺🇸University of Florida, Gainesville, Florida, United States
Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2006-09-06
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 334
- Registration Number
- NCT00372385
- Locations
- 🇬🇧
Call for Information, Call for Information, United Kingdom
🇩🇪Call For Information, Call For Information, Germany
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
- Conditions
- Interventions
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 263
- Registration Number
- NCT00336479
- Locations
- 🇺🇸
Fox Chase/ Temple Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸South Denver Gastroenterology, Englewood, Colorado, United States
🇺🇸Call for Information, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.